New Atlas
FDA approves first nasal spray diuretic for heart, liver and kidney disease
The US Food and Drug Administration (FDA) has approved the first intranasal diuretic for heart, liver and kidney disease patients, aiming to prevent a common and costly issue that results in more than ...
Fierce Pharma
J&J's Caplyta supersizes its reach with FDA nod as add-on treatment for major depressive disorder
Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...
WebMD
FDA Approves Enbumyst: First and Only Nasal Spray Diuretic for Edema From Heart, Liver, and Kidney Diseases
What Is Enbumyst, and Why Does It Matter? Enbumyst is a new nasal spray form of bumetanide (first approved by the FDA in 1983). It is a type of medicine called a loop diuretic (also known as a “water ...
Pharmaceutical Technology on MSN
J&J’s Caplyta wins MDD approval to extend revenue horizon
"J&J’s Caplyta wins MDD approval to extend revenue horizon" was originally created and published by Pharmaceutical Technology ...
pharmaphorum
J&J adds first new indication for Caplyta since takeover
The US regulator has cleared Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major ...
BioPharma Dive
J&J brain drug acquired in $14.6B buyout cleared for broader use
Caplyta, which J&J got in its acquisition of Intra-Cellular Therapies, netted a clearance in major depressive disorder that’s ...